Lack of effect of nizatidine-induced elevation of gastric pH on the oral bioavailability of dapsone in healthy volunteers

Pharmacotherapy

Volumn 22, Issue 11, 2002, Pages 1420-1425

  Itokazu, Gail S ^a   Fischer, James H ^b   Manitpisitkul, Prasarn ^b   Hariharan, Radhika ^b   Danziger, Larry H ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Jr Hospital of Cook County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDAPSONE; ANTACID AGENT; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL ANALYSIS; STOMACH PH;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DAPSONE; DRUG INTERACTIONS; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; LINEAR MODELS; MALE; NIZATIDINE; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 0036844155     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.16.1420.33698     Document Type: Article

References (14)

1. United States Public Health Service/Infectious Diseases Society of America Prevention of Opportunistic Infections Working Group. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30:S29-65.
2. Metroka CE, McMechan MF, Andrada R, Laubenstein LJ, Jacobus DP. Failure of prophylaxis with dapsone in patients taking dideoxyinosine [letter]. N Engl J Med 1991;325:737.
3. Ansel HC, Allen LV, Popovich NG, eds. Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott Williams & Wilkins, 1999:101-41.
4. Breen GA, Brocavich JM, Etzel JV, Shah V, Schaefer P, Forlenza S. Evaluation of effects of altered gastric pH on absorption of dapsone in healthy volunteers. Antimicrob Agents Chemother 1994;38:2227-9.
5. Sahai J, Garber G, Gallicano K, Oliveras L, Cameron DW. Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. Ann Intern Med 1995;123:584-7.
6. Mirochnick M, Brena A, McNamara ER, Clarke D, Pelton S. Effect of antacid on dapsone absorption. Pediatr AIDS HIV Infect Fetus Adolesc 1993;4:13-16.
7. Secor JW, Speeg VK, Meredith CG, Johnson RF, Snowdy P, Schenker S. Lack of effect of nizatidine on hepatic drug metabolism in man. Br J Clin Pharmacol 1985;20:710-13.
8. Klotz U. Lack of effect of nizatidine on drug metabolism. Scand J Gastroenterol 1987;22(suppl 136):18-23.
9. Carr K, Oates JA, Nies AS, Woosley RL. Simultaneous analysis of dapsone and monoacetyldapsone employing high-performance liquid chromatography: A rapid method for determination of acetylator phenotype. Br J Clin Pharmacol 1978;6:421-7.
10. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986;11:299-315.
11. Ozawa T, Shepard CC, Karat ABA. Application of spectrophotofluorometric procedures to some problems in Mycobacterium leprae infections in mice and man treated with dapsone (DDS), diacetyl-DDS (DADDS) and diformyl-DDS (DFD). Am J Trop Med Hyg 1971;20:274-81.
12. Cushion MT, Stanforth D, Linke MJ, Walzer PD. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob Agents Chemother 1985;28:796-801.
13. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in acquired immunodeficiency syndrome: A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990;323:776-82.
14. Mirochnick M, Cooper E, Capparelli E, et al. Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. Clin Pharmacol Ther 2001:70:24-32.